Background: This study examined the acute and sub-acute toxic effects of Terminalia chebula and Achillea wilhelmsii extracts on the murine model. Methods: In both phases, mice were assigned to intervention and control groups. At the end of study, the liver, kidney, and heart tissues were collected for histopathological studies. Results: In the acute phase of the study, the safe dose was ≤5000 mg/kg for both extracts. In sub-acute phase, LD50 (95% CI) of Achillea wilhelmsii extract was determined ≥5000 mg/kg and that of Terminalia chebula extract 2754.436 (2438-3114) mg/kg. The highest dose of T. chebula extract induced few histopathological changes. Conclusion: It will be useful to gain information on the minimum lethal doses of T. chebula and A. wilhelmsii to adopt safe doses of the two plants.
Background: Toxoplasmosis is a ubiquitous zoonotic disease caused by Toxoplasma gondii. Blood and blood products can be a probable route of T. gondii transmission, especially in patients undergoing multiple transfusions. Objectives: The aim of this cross-sectional study was to determine the prevalence of T. gondii infection among healthy blood donors in Chaharmahal and Bakhtiari province. Methods: We collected 385 blood samples from blood donors referring to the three biggest Blood Transfusion Organization Centers in the province during the period from January to June 2017. IgG and IgM antibodies against T. gondii were examined using enzymelinked immunosorbent assay. Moreover, all samples were tested by loop-mediated isothermal amplification (LAMP) method for the detection of DNA of T. gondii. Results: The seroprevalence rates of IgG and IgM anti-T. gondii antibodies were 37.9% and 1.56%, respectively. With the LAMP method, 1.56% of the samples were positive for the DNA of T. gondii. Of these, four (1.04%) were seropositive for both IgG and IgM and two (0.52%) were positive only for IgG. Moreover, statistical analyses indicated that several risk factors including gender, age, contact with cats, and consumption of undercooked meat were significantly related to T. gondii seropositivity in blood donors. Conclusions: This study indicated that anti-T. gondii antibodies were highly prevalent among apparently healthy blood donors in Southwest Iran. There was a possibility of infection transmission by blood transfusion while there is a lack of screening tests for Toxoplasma infection in the Blood Transfusion Organizations. It is strongly suggested that appropriate and sensitive screening programs be designed by the LAMP method for the detection of T. gondii in blood donors.
Background: We examined anti-Toxoplasma effect of hydroalcoholic extract of Terminalia chebula Retz (T. chebula) in cell culture and murine model. Methods: The study was conducted in Shahrekord University of Medical Sciences, Iran in 2017. Half maximal effective (concentration (EC50) of T. chebula extract and pyrimethamine was determined in infected Hela cells by using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) method. In the animal model, BALB/c mice were injected with tachyzoites (104) of T. RH strain intraperitoneally. 24h after the injection, the test groups were orally treated with 100, 200, 400 and 800 mg/kg of T. chebula extract for 7 days. The survival rate of the mice was determined and blood samples were collected to determine the amount of serum Malondialdehyde (MDA) and antioxidant capacity. Then peritoneal fluid of the mice was collected to count the number of tachyzoites and after necropsy, the pathologic changes, including the weight of liver, spleen and kidneys were investigated. The analysis of data was accomplished using SPSS. Results: EC50 values were 94.7μg/mL and 290.50μg/mL for T. chebula and pyrimethamine respectively. In the animal model, the extract of T. chebula in concentration of 100 mg/kg showed the same anti-Toxoplasma effect as pyrimethamine. This concentration of the extract decreased number of intraperitoneal tachyzoites and increased the survival rate of the mice. This extract reduced the levels of serum MDA and tissue inflammation and increased serum antioxidant capacity. Conclusion: Regarding the positive effect of extract, after more clinical trials in the animal model and standardization of the extract, it can be used as an alternative or complementary therapy for toxoplasmosis.
Background and aims: Trichomoniasis is the most common non-viral sexually transmitted infection worldwide; although it is treated by a 5-nitroimidazole drug family such as metronidazole (MTZ) with numerous side effects, and in this regard, alternative new drugs are required. Therefore, this study examined the anti-Trichomoniasis effect of the hydroalcoholic extract of some traditional medicinal plants of Iran in vitro. Methods: In this experimental study, the hydroalcoholic extracts of medicinal plants were prepared by maceration at a stock concentration of 20 mg/mL in the saline solution and then used for in vitro anti-trichomonas experiments. Trichomonas vaginalis trophozoites were isolated from the patient and cultured in a Trypticase Yeast extract Iron-Serum-33 medium. In addition, 200 μL of the culture medium containing 5×104 trophozoites was diluted in plate wells, and 10 doses were separately added on trophozoites for each extract serially diluted between 0.12 and 16 mg/mL in triplicate. The plates were incubated for 48 hours at 37 ° C with 5% CO2 . The number of trophozoites was counted with a hemocytometer and Trypan blue staining. Finally, the half maximal inhibitory concentration (IC50) was calculated by probit analysis. Results: Among the tested plants, Eugenia caryophyllata, Camellia sinensis, and Terminalia chebula Retz showed the best anti-trichomonal activity with IC50 values of 1.21, 1.62, and 1.66 mg/mL, respectively. All tested extracts had more IC50 than MTZ (IC50 100 mg/mL), an antiprotozoal drug used as a positive control. Conclusion: According to the results of this study, E. caryophylata, C. sinensis and T. chebula Retz affected the growth of T. vaginalis. Thus, it is recommended that other studies use this plant for the treatment of trichomoniasis infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.